with 2-CdA confirming an impressive response rate. cal characteristics of the patients are shown in Table 1 . 6 months after therapy, and thereafter every 6 months.
Introduction
Clinical characteristics of 30 HCL patients in CR and 10
Purine analogs have been shown to exert a potent lymphocyin PR after treatment with one single course of 2-CdA totoxic activity allowing interesting results in patients with chronic lymphoproliferative disorders. [1] [2] [3] [4] [5] [6] In particular, deoxyTotal Complete Partial responders responders coformycin (DCF) and more recently, 2-chlorodeoxyadeno-
sine (2-CdA), a molecule resistant to adenosine deaminase activity, have been shown to be very effective in the treatment Giemsa and Gomory) and for immunohistochemical studies and obtained a second CR. The remaining three relapsed patients were never retreated and still show normal peripheral with specific monoclonal antibodies such as DBA44, CD45RA and CD20, as previously described. 10 counts 22, 30 and 38 months after relapse occurred (Table 2) . In contrast, the majority of partial responders (8/10) proCriteria for response were defined according to the consensus resolution. 13 Breifly, complete remission (CR) was gressed after 8-36 months. All of them were retreated with 2-CdA at the dose indicated above. Four of these eight patients defined as the disappearance of hairy cells (Hc) from bone marrow and peripheral blood together with the regression of (50%) achieved a CR, three experienced a good clinical and hematological response and one of them died 6 months after splenomegaly and a complete recovery of peripheral blood counts (Hb Ͼ12 g/dl, platelets Ͼ100 × 10 9 /l, neutrophils the second therapeutical course because of infectious complications due to a very poor hematological recovery. Two Ͼ1.5 × 10 9 /l). Additional requirements for CR in our analysis were no Hc in bone marrow biopsies observed by routine hisadditional patients, both in CR, died after 28 and 37 months because of a second solid neoplasm (colon and lung cancer). tology and Ͻ1% of Hc by immunostaining. Partial response (PR) was characterized by a decrease in bone marrow infilSo far only three deaths have been reported and only one was indirectly related to the disease. The survival and relapse-free tration of at least 50% in addition to normalization of the peripheral blood counts. The relapse-free survival curve was calsurvival curves are shown in Figure 1 . Toxicity was generally acceptable and the most important culated according to the method of Kaplan and Meier. 14 Fisher's exact test was used for statistical analysis.
side-effect consisted of febrile episodes which were recorded in 16 patients. In seven of them, fever lasted only 24-48 h after the end of treatment and was apparently not infectionResults
All 40 HCL patients were fully evaluable for clinical and hematological response. Thirty out of 40 (75%) patients achieved a CR and the remaining 10 (25%) achieved a PR. Responses were rapid with disappearance of peripheral circulating Hc and spleen enlargement within 3 weeks from the end of 2-CdA infusion. Table 1 illustrates the CR rates according to the clinical and hematological characteristics of the patients. It is worth noting that almost all the untreated patients and those who had a bone marrow infiltration lower than 50% before starting therapy, achieved a CR. However, probably due to the small number of patients with PR, a significant correlation between either the degree of Hc bone marrow infiltration or previous treatment and clinical response has not been observed. The median follow-up duration of patients in CR at the time of writing has been 48 months (range 30-66). Five of the 30 complete responders (17%) experienced a progression of the disease after 12, 24, 26, 30 and 36 months, respectively. All five relapsed patients showed a variable Hc infiltration in the bone marrow ranging from 8 to 30%
Figure 1
Survival curve of all HCL patients and relapse-free sur-( CdA at a dose of 0.15 mg/kg/day for 5 days in 2-h infusion related. In the remaining nine patients, who showed in immunological impairment no severe opportunistic infections were recorded, probably because 2-CdA does not affect the addition severe neutropenia (neutrophils less than 1.0 × 10 9 /l), fever was related to bacterial infection, mostly due to Gramnumber and the functional activity of natural killer cells, as described in a previous study. 21 It is worth noting that two positive germs, requiring systemic antibiotics, and in three cases also granulocyte growth factor. One single patient patients with neither a familial history nor specific risk factors developed a solid tumor 28 and 37 months following therapy showed oral and eosophageal candidiasis. Conversely, clinical tolerance was good and none of the patients complained with 2-CdA. Therefore it will be necessary to follow HCL patients treated with 2-CdA, or with other purine analogs, to of nausea, vomiting, hair loss or neurotoxicity.
determine whether these agents may exert a possible oncogenic role. 22 However, the occurrence of a second malignancy has been previously observed even after treatment with Discussion ␣-IFN.
23
In conclusion, this study confirms the efficacy and the relaThe use of ␣-IFN first and more recently of DCF and 2-CdA purine analogs in the treatment of HCL, has dramatically tive safety of 2-CdA in inducing a very high proportion of complete and long-lasting remissions (Figure 1 ) in HCL improved the clinical course and the prognosis of this disorder.
14 In particular, the latter two agents, although responpatients. 24 A longer follow-up is needed to ascertain whether a subset of patients can be cured by treatment with 2-CdA. In sible for a certain degree of neutopenia and lymphocytopenia often associated with infectious complications, produce addition, a limited increase of Hc bone marrow infiltration in patients who previously obtained a CR may not necessarily higher and more prolonged CR rates as compared to ␣-IFN.
11,15-17 impair peripheral hematological values, even after prolonged time from relapse. Finally, our data show that retreatment of In the present study, treatment with 2-CdA induced a CR in 75% of HCL patients, confirming the results reported by other progressed patients with 2-CdA is still effective in obtaining durable second CR. investigators.
9, 18 Moreover, in a subset of patients with a lower degree of bone marrow infiltration, even higher CR rates were observed. This finding is somewhat in accordance with Juliusson et al 18 allowing the achievement of CR in 50% of them. of patients even after 24 months (data not shown). Despite this
